文献速递银屑病与炎症性皮肤病皮肤肿瘤自身免疫性与大疱性皮肤病

NLRP1炎症小体在皮肤癌与炎症性皮肤病中的作用

Role of the NLRP1 inflammasome in skin cancer and inflammatory skin diseases.
PubMed 文献 · Br J Dermatol · 2024-01-01

本综述阐述NLRP1炎症小体作为人角质形成细胞主要炎症小体传感器的作用机制,总结NLRP1或相关基因突变与多种单基因皮肤病及多基因自身免疫病、皮肤癌的关联,并探讨靶向该通路的未来治疗思路。

要点

  • NLRP1是公认的人角质形成细胞主要炎症小体传感器蛋白。
  • NLRP1可被病毒、紫外线B辐射和核糖毒性应激反应等多种刺激激活。
  • NLRP1通路异常涉及白斑、银屑病、特应性皮炎及鳞状细胞癌、黑色素瘤、卡波西肉瘤等。

核心结论

  • 病理性的NLRP1炎症小体失调与多种皮肤病相关,靶向该通路可能成为未来治疗方向。

研究设计与样本

  • 综述,旨在阐明NLRP1炎症小体病理失调在皮肤病中的意义并探讨靶向该通路的治疗理由。

主要发现

  • NLRP1炎症小体激活后调控IL-1β和IL-18的蛋白酶加工与活化,并诱导焦亡以暴露胞内病原体。
  • NLRP1或相关基因的特定突变与多发性自愈性掌跖癌、家族性慢性苔藓样角化病、关节炎伴角化不良的自身炎症及二肽基肽酶9缺乏症等罕见单基因皮肤病相关。
  • NLRP1通路功能障碍涉及白斑、银屑病、特应性皮炎以及鳞状细胞癌、黑色素瘤和卡波西肉瘤等皮肤癌。
  • 新兴证据提示NLRP1还涉及系统性红斑狼疮、寻常型天疱疮、艾迪生病、Papillon-Lefèvre综合征和麻风。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inflammasomes are cytoplasmic protein complexes that play a crucial role in protecting the host against pathogenic and sterile stressors by initiating inflammation. Upon activation, these complexes directly regulate the proteolytic processing and activation of proinflammatory cytokines interleukin (IL)-1β and IL-18 to induce a potent inflammatory response, and induce a programmed form of cell death called pyroptosis to expose intracellular pathogens to the surveillance of the immune system, thus perpetuating inflammation. There are various types of inflammasome complexes, with the NLRP1 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-1) inflammasome being the first one identified and currently recognized as the predominant inflammasome sensor protein in human keratinocytes. Human NLRP1 exhibits a unique domain structure, containing both an N-terminal pyrin (PYD) domain and an effector C-terminal caspase recruitment domain (CARD). It can be activated by diverse stimuli, such as viruses, ultraviolet B radiation and ribotoxic stress responses. Specific mutations in NLRP1 or related genes have been associated with rare monogenic skin disorders, such as multiple self-healing palmoplantar carcinoma; familial keratosis lichenoides chronica; autoinflammation with arthritis and dyskeratosis; and dipeptidyl peptidase 9 deficiency. Recent research breakthroughs have also highlighted the involvement of dysfunctions in the NLRP1 pathway in a handful of seemingly unrelated dermatological conditions. These range from monogenic autoinflammatory diseases to polygenic autoimmune diseases such as vitiligo, psoriasis, atopic dermatitis and skin cancer, including squamous cell carcinoma, melanoma and Kaposi sarcoma. Additionally, emerging evidence implicates NLRP1 in systemic lupus erythematosus, pemphigus vulgaris, Addison disease, Papillon-Lefèvre syndrome and leprosy. The aim of this review is to shed light on the implications of pathological dysregulation of the NLRP1 inflammasome in skin diseases and investigate the potential rationale for targeting this pathway as a future therapeutic approach.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Calabrese L, Fiocco Z, Mellett M, et al. Role of the NLRP1 inflammasome in skin cancer and inflammatory skin diseases. Br J Dermatol. 2024. PMID: 37889986. doi:10.1093/bjd/ljad421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。